Transition Therapeutics - Ordinary Shares (TTHI) Quote

* * $TTHI Video Chart 06-30-16 * *

Link to Video - click here to watch the technical chart video

Thank you very much OPK

Pop baby pop!

We'll see, but a 70% drop's not in the cards. Company assets are worth .60 ps if they sold out.

That dog don't hunt.

The drug did not fail. LLY is not taking it forward to P3.
TTHI can take it forward, or they can re-partner with someone else.

TT401 is a once-weekly administered oxyntomodulin analog, with dual agonist activity on the GLP1 and Glucagon receptors. TT401 is the most clinically advanced drug candidate among the new class of GLP1-glucagon receptor dual agonists. The product profile for this class of diabetes drug candidates is to provide type 2 diabetes individuals with blood-glucose control and greater weight loss than GLP1 single agonists.

In the recently completed Phase 2 study of 420 type 2 diabetes individuals, the highest dose of TT401 once-weekly administered peptide demonstrated significantly superior weight loss to currently approved extended release exenatide and placebo after 12 and 24 weeks of treatment. TT401 also provided similar HbA1c reduction as exenatide at weeks 12 and 24. The study demonstrated that TT401 had an acceptable safety and tolerability profile consistent with GLP-1 single agonists.

Thinking 70% drop for drug failure.

You're right. It's unbelievable. I was expecting a surge in volume, and especially buy volume. Under 100,000 is incredibly paltry! Nonetheless, it won't be long before it hits dollar hand and stays there.

Shocking lack of volume on this news.

Really good flip. This ticker has a lot of potential to hit higher highs, as was evidenced by that HOD at open.

In at 85 cent out at a dollar. Reload around 50?

This, from Fierce Biotech, if you haven't read it.

Canada's Transition Therapeutics ($TTHI) is touting positive Phase II data for a once-a-week GLP-1 treatment, triggering a decision point for partner Eli Lilly ($LLY), which bought into the program in a $247 million deal.

The treatment, TT401 is a dual-acting agent for Type 2 diabetes, boosting both the body's GLP-1 receptors--much like Lilly's Trulicity--as well as its glucagon receptors with a double mechanism Transition says can help curb appetite while controlling blood glucose.

In a 12-week study on 420 diabetics, Lilly and Transition tested four dosages of TT401 against AstraZeneca's ($AZN) GLP-1 drug Bydureon and placebo. TT401 demonstrated blood sugar improvements similar to--but not better than--Bydureon, Transition said, and beat out placebo by a statistically significant margin on that measure.

The highest dose of TT401, 50mg, made a significant difference in weight loss compared with AstraZeneca's treatment and placebo, according to the company, and safety was comparable between the TT401 and Bydureon arms.

Now it's up to Lilly whether to take TT401 into Phase III. Lilly licensed the treatment in 2013, paying $7 million up front and promising up to $240 million more if TT401 makes it to market. If Lilly decides to pass on the drug, Transition has the option of moving forward on its own or finding a new partner, the company said.

Lilly will have to decide whether TT401's purported benefits can differentiate it in a fast-crowding space. Trulicity won approval in 2014, contending with Novo Nordisk's ($NVO) market-leading GLP-1 drug Victoza, which is dosed daily. Since then, Novo has embarked on a 6-trial effort to support semaglutide, its own weekly GLP-1 treatment, and rival therapies from GlaxoSmithKline ($GSK) and Sanofi ($SNY) have won approvals around the world.

Lilly didn't respond to a request for comment on the TT401 program Monday.

The two companies have been collaborating for nearly a decade with little clinical success. Lilly licensed TT-223, another diabetes drug, in 2008 but discarded the program two years later after a trial failure. The same came of TT-701, a Lilly-licensed treatment for arthritis pain that never made it past Phase I. The two are now working together on TT701, a Phase II drug designed to boost muscle mass.

The question though, are they good enough to move it forward?

Results are good enough for milestone payment.

This is a long shot

THIS WILL CLOSE @ 2.32

Dude your a comedian at its best...love your posts..they make me laugh ..really

Free, you're so funny, just as funny as TTHI. LOL. I were hoping this stock would have ran. They're working on a much needed drug. I like to get back into this one. I have been on TTHI for a while. I can double up my position when the stock stop falling.

GLTA.

lol

I SHOULD STILL BE SHORT OH WELL

TTHI I AM OUT . 5% LOSS

I have no comment for you

VOLUME DRIED UP PUT A FORK IN THIS POS

Protection sell 2.28

GOOD LUCK WITH THAT HOPE YOU WIN!!! NOT LOOKING GOOD BRO

i am in already..@ 2.42

SURE TRADER BRO GET IT OR WATCH ON THE SIDELINES

FREEMONEY WILL BE THE NEXT TIM GRITTANI

TTHI IN AT 2.42

COVERED @ 2.40

TTHI only made 20% move...max...its weak based on volume...on the sidelines...need to see a break out...or no deal

it did not spike enough and on the given volume..dangerous to short at these levels bro..why you do that?

WILL COVER @ 2.25

HUH???? omg

SHORT

2.53??? why ??? stop playing bingo here...

IM IN @ 2.53 giddy up

http://finance.yahoo.com/news/transition-therapeutics-alzheimer-drug-effective-104642387.html;_ylt=A0LEV1Trrx9W3YYAFnlXNyoA;_ylu=X3oDMTByMDgyYjJiBGNvbG8DYmYxBHBvcwMyBHZ0aWQDBHNlYwNzYw--

BOOM BOOM !!!!

TTHI WAITING FOR RETRACE..IF NO RETRACE..NO DEAL

$TTHI

It is. Although a smaller target population, it is still well worth the effort as there is no drug treatment available at this time.

I been sitting on this one for months. Nice big break for today.

Someone gets it. :) and their is more

Their other drug which will report trial results this year is a diabetes drug. They are partnered with LLY on this and LLY is running the trial.

It's worth noting that LLY already has an approved diabetes drug on the market. If TT-401 had not shown promise, there would be no reason at all for them to buy a piece of this and head up the trial.

Other Drugs?

Any hope for the other drugs TTHI is tedting?

Dang! Crap shoot run to HERO!

Chasing the low.

cmon $1.00!!!

looks like it's just gonna keep bleeding, and fast. under $2 today?

$60million in cash!!!!! their main product is huge! oversold